Skip to main content
QDELQuidelOrtho CorporationSell5.4·$14.01
QDEL · Concentration risk · 10-K extracted

QuidelOrtho (QDEL) concentration risks

Updated

The most significant concentration QuidelOrtho discloses is single and sole source suppliers, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Source: QuidelOrtho’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗

At a glance

Disclosed-size breakdown · 3 disclosed concentrations

HIGH1
MEDIUM1
LOW1
Disclosed concentrations

Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).

HIGHOutside partySupplier

single and sole source suppliers

“10-K Item 1A: 'our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers'”
— SEC 10-K · filed Feb 2026
MEDIUMOutside partyCustomer

key distributors

“10-K Item 1A: 'we rely on certain key distributors for the sales of some of our products'”
— SEC 10-K · filed Feb 2026
LOWBuilt-inProduct / Revenue mix
15%

respiratory products

“10-K Item 1A: 'sales of our respiratory products accounted for approximately 15% of our total revenues for the year ended December 28, 2025'”
— SEC 10-K · filed Feb 2026
TrendMatrix Research · concentration synthesis

What these concentrations mean together

updated 2026-07-06

QuidelOrtho's concentration risk runs through its supply chain more than its customer or product mix. The company discloses reliance on a small number of contract manufacturers and a large number of single and sole source suppliers — a dependency exposure disclosed at a significant scale, with no readily available alternative in place for at least some of these relationships. Layered on top, the company also relies on certain key distributors for the sales of some of its products, a more moderate dependency on the go-to-market side. By contrast, the company's product-line concentration is modest: respiratory products accounted for approximately 15% of total revenues, a comparatively small share of the overall business. Netting these together, the supplier and manufacturer dependency is the most consequential exposure — a disruption at any single- or sole-source supplier could affect production broadly — while the distributor reliance adds a secondary, more moderate dependency on the demand side. The respiratory product concentration, being a modest share of revenue, is unlikely on its own to move the investment verdict.

For the engine’s reasoning on QDEL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Industry peers · Medical Devices

Peer concentration profile

SymbolNameHIGHMEDIUMLOWTotal
AORTArtivion, Inc.4408
AVNSAvanos Medical, Inc.2013
QDEL●QuidelOrtho Corporation1113
ATECAlphatec Holdings, Inc.1102
ABTAbbott Laboratories1001
AHCOAdaptHealth Corp.0000

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.

Concentration disclosures are extracted verbatim from SEC 10-K filings; the disclosed-size classification and the synthesis above are engine-derived. Size reflects how large each exposure is against fixed share thresholds (HIGH >50%, MEDIUM 25–50%, LOW <25% or an explicit diversification statement), not a judgment of how dangerous it is, and is not a buy/sell rating, a price target, or a view on the stock. Not a complete list of risk factors — see the full filing.

Home › Stocks › QDEL › Concentration risk
QDEL concentration risks — customer, geographic & supplier exposure | TrendMatrix